
An experimental therapy that uses the body’s own immune system cells may beat a standard treatment for patients with advanced melanoma, a new clinical trial finds. Researchers found that the therapy doubled the amount of time melanoma patients lived without their skin cancer progressing, versus a long-used drug called ipilimumab (Yervoy). The approach, called tumor-infiltrating… read on > read on >